← Drug database

Clopidogrel Teva Pharma B.V. (clopidogrel)

Generic
Region
🇪🇺 EU
Active substance
clopidogrel
Company
Teva Pharma B.V.
Status
Withdrawn
Therapeutic area
Peripheral Vascular Diseases; Acute Coronary Syndrome; Myocardial Infarction; Stroke
EU approval
Thu 16 Jun 2011
Designations
Generic
Application
EMEA/H/C/001226
ATC
B01AC04
Official record
www.ema.europa.eu

Indication

Prevention of atherothrombotic events Clopidogrel is indicated in: adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease; adult patients suffering from acute coronary syndrome: non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA); ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy. Prevention of atherothrombotic and thromboembolic events in atrial fibrillation In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists (VKA) and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.

Regulatory milestones

No milestones recorded in the last year.

Same substance in other markets

Follow Clopidogrel Teva Pharma B.V.

Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.